Team

Chief Scientific Officer, Script Molecular Srilekha Deka, MD, PhD

Srilekha Deka is an experienced Director of R&D, a skilled scientist and a qualified team leader. With two decades of R&D experience in the biotechnology industry, she is passionate about the field of molecular diagnostics. Her experience includes working with small start-up companies like Handylab all the way to working at Roche, one of the largest biotech companies and a leader in the field. This gives Srilekha the distinctive advantage of being able to understand the needs of both the start-up environment and the more established environment of large companies, and tailor the services of Script Molecular to meet their unique needs.

She has led teams through more than ten successful submissions to FDA and other regulatory agencies including the first 510(k) clearance for the BD Max platform and the Meridian Bioscience Alethia platform. In these projects, Srilekha worked on all the necessary documentation required for commercialization and regulatory approval. She led the R&D team at Molecular Designs through a successful ISO13485 certification and rapid commercialization of assays for SARS-CoV-2/FluA/FluB/RSV and Mpox.

Srilekha holds an M.D. from Gauhati Medical College, India and a Ph.D. in Biomedical Science from the Quillen College of Medicine, ETSU. She went on to complete her post-doctoral work in Immunology from Wayne State University, Detroit and has authored multiple publications in peer reviewed journals. Srilekha is enthusiastic about leveraging her broad knowledge of scientific and technical principles to contribute to the advancement of diagnostic methods for improved treatment and disease outcomes for patients.

Chief Commercial Officer, Script Molecular Manohar Furtado, PhD

Manohar Furtado brings 40 plus years of experience working with large, mid-size and small biotech companies and bringing their technology to the market. He has worked for pioneering biotechnology organizations including Bio-Rad, Cepheid and Thermo Fisher Scientific and with innovative companies like Advanced Cell Diagnostics to position their RNAScope ISH technology for biomarker analysis, Vibrant Health for their novel peptide/PNA microarray for infectious and auto- immune diseases, Apton Biosystems for their Super-Res multiomic system and LexaGene for their automated platform for rapid pathogen detection.